Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Feng‐Hua Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1016-6867; OpenAlex author ID A5100603154. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 10

  1. Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, p… Co-author DOI 10.1186/s12943-025-02437-0↗
  2. Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer. Co-author DOI 10.2147/itt.s530434↗
  3. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.12.008↗
  4. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Co-author DOI 10.1177/17588359231186029↗
  5. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  6. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single… Co-author DOI 10.3390/curroncol28010023↗
  7. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s40880-019-0367-7↗
  8. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Co-author DOI 10.7150/jca.14185↗
  9. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Co-author DOI 10.1186/1479-5876-11-249↗
  10. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Co-author DOI 10.1002/ijc.26376↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guifang Guo · 4 shared papers, 2020–2025 · strength 0.82
  2. Xujia Li · 2 shared papers, 2023–2024 · strength 0.40
  3. Shengping Li · 2 shared papers, 2023–2024 · strength 0.40
  4. Yuhong Li · 5 shared papers, 2012–2024 · strength 0.39
  5. Qi Quan · 2 shared papers, 2020–2024 · strength 0.31
  6. Miao‐Zhen Qiu · 4 shared papers, 2012–2024 · strength 0.31
  7. Silan Huang · 1 shared paper, 2025 · strength 0.30
  8. Jinsheng Huang · 1 shared paper, 2023 · strength 0.20
  9. Yun‐Xin Lu · 1 shared paper, 2025 · strength 0.20
  10. Dongsheng Zhang · 1 shared paper, 2025 · strength 0.20
  11. Feng Wang · 1 shared paper, 2025 · strength 0.20
  12. Ming-Ming He · 1 shared paper, 2025 · strength 0.20
  13. Rui‐Hua Xu · 4 shared papers, 2012–2019 · strength 0.20
  14. Dongsheng Zhang · 3 shared papers, 2012–2020 · strength 0.20
  15. De‐Shen Wang · 3 shared papers, 2012–2019 · strength 0.17
  16. Zhi‐Qiang Wang · 2 shared papers, 2012–2019 · strength 0.12
  17. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  18. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  19. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  20. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  21. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  22. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  23. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  24. Gang Ren · 1 shared paper, 2022 · strength 0.09
  25. Jie Chen · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.